anti-nfP2X7 CAR T-cell therapy (Biosceptre)

N/A

Report date: 2025/03/18 18:10:20

Base Information

Drug Nameanti-nfP2X7 CAR T-cell therapy (Biosceptre)

Drug Alias Nameautologous direct CAR T-cells (Biosceptre)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionP2X purinoceptor 7 modulators

TargetsP2X purinoceptor 7

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBiosceptre International Ltd

China Registration ClassN/A

Develop Information

Active CompaniesBiosceptre International Ltd

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A